证券代码：920729 证券简称：永顺生物 公告编号：2026-001 广东永顺生物制药股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 面对下游养殖业持续低迷、行业竞争加剧及产品单价持续下行等不利因素影 响，公司管理层始终秉承"以质量求生存、以创新谋发展"的经营理念，通过拓 展海外市场、加强应收账款管控、强化内部管理及落实提质增效措施稳步提升公 司整体经营质量。 报告期内，公司实现营业收入 23,816.63 万元，同比下降 11.46%；实现归属 于上市公司股东的净利润 4,056.05 万元，同比增长 1.04%；实现归属于上市公司 股东的扣除非经常性损益的净利润为 2,801.08 万元，同比下降 9.61%。 截至本报告期末，公司总资产为 79 ...

Financial Performance - Total revenue for 2025 reached RMB 840.85 million, a year-on-year increase of 7.97%[4] - Net profit attributable to shareholders was RMB 98.52 million, reflecting a 31.79% increase compared to the previous year[4] - The net profit excluding non-recurring gains and losses was RMB 94.65 million, up 55.75% year-on-year[4] - Basic earnings per share increased to RMB 0.98, a growth of 30.67% from the previous year[4] - Gross margin improved to 31.92%, an increase of 3.57 percentage points compared to the same period last year[6] - Total assets at the end of the reporting period were RMB 3,086.01 million, a 4.68% increase from the beginning of the period[4] - Shareholders' equity attributable to the parent company was RMB 1,867.65 million, up 3.99% from the start of the period[4] - Overseas sales revenue was RMB 216.92 million, representing a 9.00% increase and accounting for 25.80% of total revenue[6] Strategic Focus - The company plans to focus on four key areas: petrochemicals, energy chemicals, renewable resources, and renewable energy in 2026[7] - The company aims to transition its business model from new material manufacturing to comprehensive technical services for high-quality development[7]

证券代码：920895 证券简称：花溪科技 公告编号：2026-007 新乡市花溪科技股份有限公司 2025 年年度业绩快报公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 单位：元 | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 65,692,699.20 | 82,185,348.55 | -20.07% | | 利润总额 | -4,036,032.54 | 1,848,083.53 | -318.39% | | 归属于上市公司 | -4,140,824.94 | 1,562,572.66 | -365.00% | | 股东的净利润 | | | | | 归属于上市公司 股东的扣除非经 常性损益的净利 | -4 ...

Financial Performance - The company's operating revenue for 2025 was CNY 476,383,689.21, a decrease of 1.46% compared to CNY 483,455,835.37 in the previous year[4] - The total profit for the period was CNY 63,646,433.13, down 37.15% from CNY 101,273,322.98 year-on-year[4] - Net profit attributable to shareholders was CNY 56,942,151.48, a decline of 34.48% from CNY 86,913,496.38 in the previous year[4] - Basic earnings per share decreased to CNY 0.70, down 47.37% from CNY 1.33 in the previous year[4] Assets and Equity - Total assets increased by 11.16% to CNY 1,202,007,126.95 from CNY 1,081,378,376.36 at the beginning of the period[5] - Shareholders' equity attributable to the company rose by 7.01% to CNY 942,095,710.15 from CNY 880,397,621.46[5] Revenue and Strategy - The increase in net profit was primarily affected by a decrease in revenue from high-margin products and an increase in accounts receivable, leading to higher credit impairment losses[7][8] - The company continued to invest in new product development, with increased R&D expenses compared to the previous year[8] - The company adjusted its sales strategy to focus on the sales of parts and leasing services for support vehicles, which saw rapid revenue growth[7] Audit and Final Data - The final financial data for 2025 is subject to audit and may differ from the preliminary figures reported[9]

Financial Performance - The company's operating revenue for 2025 was CNY 972,517,947.94, a decrease of 7.69% compared to the previous year[4] - The total profit for the period was CNY 75,098,511.85, down 59.91% year-on-year[4] - Net profit attributable to shareholders was CNY 65,191,755.66, reflecting a decline of 59.72% compared to the same period last year[4] - Basic earnings per share decreased to CNY 0.42, down 60.38% from CNY 1.06 in the previous year[4] Assets and Equity - Total assets increased by 20.20% to CNY 2,477,419,431.12 compared to the beginning of the period[5] - Shareholder equity attributable to the company rose by 2.97% to CNY 1,076,021,560.46[5] - The company's share capital increased by 39.90% to CNY 156,750,720.00 due to a rights issue[6] Market Conditions and Strategy - The decline in performance was attributed to a slowdown in the lithium battery industry and increased market competition[6] - The company has received sufficient orders as the industry gradually recovers, but revenue recognition from new orders has not yet occurred due to delivery cycles[6] - The company is increasing investment in market expansion and R&D, leading to higher operating expenses[6]

证券代码：920931 证券简称：无锡鼎邦 公告编号：2026-002 无锡鼎邦换热设备股份有限公司 2025 年年度业绩快报公 告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年 年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、2025 年年度主要财务数据和指标 报告期内，公司预计实现营业收入 311,544,787.77 元，同比下降 22.30%；归 属于上市公司股东的净利润 10,587,778.94 元，同比下降 72.96% ；归属于上市公 司股东的扣除非经常性损益的净利润 8,223,482.82 元，同比下降 78.27%；基本每 股收益 0.11 元，同比下降 76.09%。 报告期末，预计公司总资产为 818,448,823.40 元，较报告期初增长 18.85%； 归属于上市公司股东的所有者权益为 392,534,099.16 元，较报告期初增长 0.3 ...

| 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 1,071,886,391.22 | 1,061,608,140.89 | 0.97% | | 利润总额 | 29,786,021.52 | 26,157,738.24 | 13.87% | | 归属于上市公司股 | 25,777,563.54 | 20,325,941.04 | 26.82% | | 东的净利润 | | | | | 归属于上市公司股 东的扣除非经常性 | 25,644,616.31 | 14,014,496.99 | 82.99% | | 损益的净利润 | | | | | 基本每股收益 | 0.16 | 0.12 | 33.33% | | 加权平均净资产收 益率%（扣非前） | 4.12% | 3.25% | - | | 加权平均净资产收 益率%（扣非后） | 4.10% | 2.24% | - | | 项目 | 本报告期末 | 本报告期初 | 变动比例% | | 总资产 | 849,329,516.04 | 784,478,777.76 | 8.27% | | 归 ...

证券代码：920245 证券简称：威博液压 公告编号：2026-015 | 单位：元 | | --- | | 项目 | 本报告期 | 上年同期 | 变动比例% | | --- | --- | --- | --- | | 营业收入 | 341,134,431.34 | 337,881,137.14 | 0.96% | | 利润总额 | 15,268,754.36 | 24,663,429.99 | -38.09% | | 归属于上市公司股 | 12,841,171.12 | 20,696,101.53 | -37.95% | | 东的净利润 | | | | | 归属于上市公司股 | 8,149,971.81 | 18,183,341.49 | -55.18% | | 东的扣除非经常性 | | | | | 损益的净利润 | | | | | 基本每股收益 | 0.26 | 0.42 | -37.82% | | 加权平均净资产收 | 3.74% | 6.23% | - | | 益率%（扣非前） | | | | | 加权平均净资产收 | 2.37% | 5.47% | - | | 益率%（扣非后） | | | | | ...

Financial Performance - The company's operating revenue for the reporting period is expected to be ¥169,713,804.31, an increase of 0.96% compared to the same period last year[6] - The total profit is expected to be ¥48,765,726.10, a decrease of 18.46% year-on-year[6] - The net profit attributable to shareholders is expected to be ¥35,180,806.67, down 15.49% from the previous year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be ¥28,934,305.48, an increase of 2.37% year-on-year[6] - Basic earnings per share are expected to be ¥0.40, a decrease of 14.89% compared to the previous year[6] Assets and Equity - Total assets at the end of the reporting period are expected to be ¥680,477,675.69, an increase of 5.06% from the beginning of the period[6] - Shareholders' equity attributable to the company is expected to be ¥558,391,326.25, an increase of 3.56% from the beginning of the period[6] Revenue Drivers and Risks - The expected increase in operating revenue is attributed to the company's active market expansion efforts[7] - The decrease in total profit is primarily due to the absence of non-recurring gains from asset disposals in the previous year[7] - The financial data presented is preliminary and has not been audited, cautioning investors about potential risks[8]

证券代码：688238 证券简称：和元生物 公告编号：2026-006 和元生物技术（上海）股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以和元生物技术（上海）股份有限公司（以下简称"公司"）2025 年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 26,766.34 | 24,814.92 | 7.86 | | 营业利润 | -21,800.20 | -31,045.08 | 不适用 | | 利润总额 | -21,832.44 | -31,262.71 | 不适用 | | 归属于母公司所有者的净利润 | -22,071.57 | -32,181.30 | 不适用 | | 归属于母公司所有 ...